儿科喉瘤:当低血糖症显示出脑瘤时. 一个说明性的案例
Oualid M Hmamouche1, Marouane Hammoud1, Faycal Lakhdar1
1Department of Neurosurgery, Hassan II University Hospital, Fez, Morocco.
Journal of neurosurgery. Case lessons
|February 2, 2026
概括
在儿童中,喉瘤很少会导致严重的低血糖和昏迷. 及时内分泌评估和成像对于早期诊断和有效管理这种罕见表现至关重要.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 儿科神经外科 儿科神经外科
- 在瘤学瘤学.
背景情况:
- 大脑瘤 (CPs) 通常伴有诸如内高血压,视力障碍或生长衰竭等症状.
- 低血糖作为喉瘤的初始症状是非常罕见的,表明下丘脑-垂体功能障碍.
研究的目的:
- 为了突出严重低血糖症的喉瘤的罕见表现.
- 强调及时内分泌评估和对未解释的儿科低血糖症的成像的重要性.
主要方法:
- 一份病例报告显示,一名4岁女孩昏迷并患有严重的低血糖症.
- 诊断工作包括内分泌检测和脑MRI.
- 细胞上细胞质 (瘤) 经过手术切除.
主要成果:
- 患者经历了反复出现的低血糖症,中央上腺功能不全和甲状腺功能低下症.
- 大脑MRI显示了囊性细胞-细胞上质体.
- 组织病理学证实了阿达曼蒂诺马图斯膜瘤;手术后低血糖症通过激素替代治疗得到解决.
结论:
- 在儿童中,瘤异常可能出现重复性低血糖症和昏迷症.
- 及时内分泌评估和细胞成像对于无法解释的儿科低血糖症至关重要.
- 涉及神经外科和内分泌学的多学科管理是有利结果的关键.
相关概念视频
Hypoglycemia and Glucagon
983
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
983
Pharmacokinetics in Pediatric Patients: Drug Excretion
262
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
262
Pharmacokinetics in Pediatric Patients: Drug Distribution
304
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism
226
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
226
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
296
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
296
Tumor Immunotherapy
1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K


